Docoh
Loading...

124 results

Filter options loading...
Top filers
Top filing types
Recent filing years
10-Q
2021 Q2
EX-31.1
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b. Any fraud, whether
10-Q
2021 Q2
EX-31.2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b. Any fraud, whether
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
IN THIS AGREEMENT, OR (C) DAMAGES TO WHICH A PARTY MAY BE ENTITLED FOR THE WILLFUL MISCONDUCT, INTENTIONAL BREACH OR FRAUD OF THE OTHER PARTY. ARTICLE XI
10-Q
2021 Q1
EX-31.1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
10-Q
2021 Q1
EX-31.2
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role
10-K
EX-31.2
htocs7atyk 3qa
24 Mar 21
Annual report
8:00pm
10-K
EX-31.1
l8x3yw980jkxjr9hd
24 Mar 21
Annual report
8:00pm
10-K
xt1 5hqtc
24 Mar 21
Annual report
8:00pm
D
6cj ucl0yz6aml
19 Feb 21
$10.24M in equity / options, sold $10.24M, 18 investors
9:26am
8-K
EX-10.1
oadxne58
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
10-Q
EX-31.1
3xk092c
12 Nov 20
Quarterly report
4:01pm
10-Q
EX-31.2
j3nuxxjx
12 Nov 20
Quarterly report
4:01pm
8-K
EX-10.1
z8spnbuuqv5q67vor
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
8-K
EX-1.1
ezxhqdn5j6mqb111
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
fj77x7j6
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
quaskf9ya2v9
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
vc7l7 762
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.4
fedv6ae0z9
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-1.1
zlycr5kl40pp4m6wv
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-3.2
5h4fw34 l047tz
16 Sep 20
IPO registration (amended)
8:00pm